iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
In a midday roundup published October 1, 2026, CNBC reported sharp gains for Accenture, Synopsys, United Therapeutics and Vicor, alongside notable moves in several other stocks. The reported catalysts ranged from quarterly results and company forecasts to a court ruling and analyst commentary. These are reported moves from that trading session, not indications of future returns.
Biggest reported midday movers
The figures and explanations below are claims in CNBC’s October 1, 2026 roundup, reproduced by Newcome.ca. They have not been independently checked against intraday market data, company filings or the underlying court record.
| Company | Reported move | Reported catalyst | What the evidence represents |
|---|---|---|---|
| Accenture | Up 18% | Fiscal fourth-quarter results exceeded the company’s revenue guidance and FactSet consensus; earnings per share also beat expectations. | Reported quarterly results and comparisons with guidance and consensus. |
| Synopsys | Up more than 8% | Investor-day strategy and long-term targets, alongside a strategic partnership announcement with OpenAI. | A company forecast for 2027 revenue growth, not realized revenue. |
| United Therapeutics | Up 6% | A Delaware federal court ruling that Liquidia’s lung treatment infringed a United Therapeutics patent. | Reported legal development; the roundup also relayed an analyst’s interpretation. |
| Liquidia | Down 15% | The same reported patent ruling involving its lung treatment. | Reported market reaction to a legal development. |
| Vicor | Up almost 10% | Raised its third-quarter revenue-growth outlook, citing increased royalties under a previously announced nonexclusive Vertical Power Delivery license. | Revised company guidance, not a reported final quarter result. |
| McCormick | Down more than 2% | Quarterly results; the roundup also noted a planned combination with Unilever’s foods business. | Reported results and a planned transaction. |
| McKesson | Not stated in the roundup | Reaffirmed fiscal 2027 EPS guidance and extended its CVS Health distribution partnership through June 2032. | Company guidance and a reported partnership extension. |
| Constellation Energy | Up nearly 3% | Announced a reported 20-year deal with Amazon supporting capacity expansion at a Maryland nuclear power plant. | Reported market reaction to a long-term energy deal. |
| Sigma Lithium | Down 16% | Temporarily suspended mining and industrial production amid legal proceedings and a delayed court review. | Reported operational action and legal-process development. |
| Acuity Brands | Down nearly 4% | Its forward net-sales growth guidance for Acuity Intelligent Spaces was characterized as slightly below consensus. | Forward company guidance, with the comparison attributed to StreetAccount. |
| BJ’s Restaurants | Up about 5% | Mizuho upgraded the shares to outperform and raised its target price by $2 to $76. | Analyst rating, target and estimates, rather than company-reported results. |
| Corteva | Down 84% for the remaining shares, as reported | Formal spinoff of its Vylor seed and genetics business. | Roundup-reported move associated with a corporate separation; the unusually large figure was not independently verified. |
What drove Accenture and Synopsys higher?
Accenture: quarterly results beat the cited benchmarks
The roundup reported Accenture revenue of $18.7 billion for its fiscal fourth quarter, above company guidance of $17.8 billion to $18.4 billion and FactSet’s $18.3 billion consensus. Earnings were reported at $3.29 per share, above expectations. The article attributed the stock’s 18% gain to the results.
Synopsys: investor-day plans and an OpenAI partnership
Synopsys gained more than 8% after outlining strategy and long-term targets at an investor day and announcing a strategic partnership with OpenAI. The company expected 2027 revenue growth of 15%, to $11.1 billion to $11.2 billion, compared with analyst consensus of $10.82 billion, according to the roundup. That figure is a forecast, not revenue already earned.
#1 Best Overall
What was behind the healthcare and semiconductor-related moves?
United Therapeutics and Liquidia: a reported patent ruling
The roundup said a Delaware federal court ruled that Liquidia’s lung treatment infringed a United Therapeutics patent. United Therapeutics shares rose 6%, while Liquidia fell 15%, as reported. The article also relayed BTIG’s interpretation of what the ruling could mean; that is an analyst view and should not be confused with the court’s stated outcome.
Vicor: higher third-quarter growth guidance
Vicor raised its third-quarter revenue-growth outlook to more than 30%, from at least 20%, and its shares rose almost 10%, according to the roundup. The company cited increased royalties under its previously announced first nonexclusive Vertical Power Delivery license. The growth figure is guidance, not a final reported result.
Rank #2
- Comes with secure packaging
- Easy to read text
- It can be a gift option
What moved the other stocks in the roundup?
McCormick: results and a planned food-business combination
McCormick’s adjusted third-quarter earnings were reported at $0.86 per share, versus $0.76 expected, while revenue was $2.02 billion, versus $1.98 billion consensus. Shares nevertheless fell more than 2%, according to the roundup. It also noted a planned combination with Unilever’s foods business, then scheduled to close by mid-2027.
Free tools Windows power users keep installed
One-click scans. No signup required.
McKesson: guidance reaffirmed and CVS partnership extended
McKesson reaffirmed its fiscal 2027 earnings-per-share guidance and extended its distribution partnership with CVS Health through June 2032. The roundup said McKesson’s fiscal second-quarter results were due November 4; it did not state a share-price move for the stock.
Constellation Energy: long-term deal with Amazon
Constellation Energy gained nearly 3% after announcing a reported 20-year agreement with Amazon supporting capacity expansion at a Maryland nuclear power plant, the roundup said.
Sigma Lithium: production pause amid legal proceedings
Sigma Lithium shares fell 16%. The roundup said the company temporarily suspended mining and industrial production after a Brazilian federal appeals court delayed for 15 days its review of the company’s defense related to a lawsuit filed by a nongovernmental organization.
Acuity Brands: guidance characterized as below consensus
Acuity Brands fell nearly 4%. StreetAccount characterized the company’s forward guidance for low- to mid-teens net-sales growth in Acuity Intelligent Spaces as slightly below consensus, according to the roundup.
Recommended Free Tools
BJ’s Restaurants: Mizuho upgrade and sales estimate
BJ’s Restaurants rose about 5% after Mizuho upgraded the stock to outperform and raised its target price by $2, to $76. The roundup quoted Mizuho as saying: “Based on our strong checks, we increase our Q3 [same-store sales] growth estimate to 5.5% from 4.6%, above consensus of 4.3%,” and reported that the firm expected further estimate revisions through 2027. The quoted assessment is attributed to Mizuho; no individual speaker was named.
Best Value
Corteva: Vylor spinoff and an unusually large reported move
Corteva formally spun off its Vylor seed and genetics business. The roundup reported that Corteva’s remaining shares fell 84% after the separation. Because the figure is unusually large and has not been independently verified here, treat it as the roundup’s claim rather than a confirmed market-data reading.
Quick Recap
How to interpret a midday stock-movers list
- Separate results from forecasts. Accenture’s revenue and earnings figures were reported as quarterly results; Synopsys’s 2027 revenue range and Vicor’s third-quarter growth outlook were forward-looking company expectations.
- Separate events from interpretations. The reported patent ruling is a legal development. BTIG’s interpretation and Mizuho’s BJ’s Restaurants estimates are analyst commentary.
- Keep the time frame in view. These are moves described in a midday roundup for October 1, 2026, not a market-wide study or a prediction of what the stocks will do next.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
